Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajesh Pandey

Rheumatology Franklin Lakes, NJ Medical Doctor

NPI 1144486200 CMS profile 424517

784 Franklin Ave, Ste 250, Franklin Lakes, NJ 07417

Open in the dashboard

General payments

$5,640

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajesh Pandey of Franklin Lakes, NJ is reported in the CMS Open Payments database as having received $5,640 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $510 23
2024 General $781 46
2023 General $958 57
2022 General $959 35
2021 General $881 56
2020 General $760 53
2019 General $790 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajesh Pandey
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Rajesh Pandey were reported at $510. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Rajesh Pandey Rheumatology median Middle half National median
2019 $790 $744 $153–$2,687 $163
2020 $760 $462 $98–$2,027 $114
2021 $881 $531 $101–$2,153 $132
2022 $959 $627 $125–$2,303 $149
2023 $958 $741 $145–$2,524 $160
2024 $781 $830 $166–$2,660 $164
2025 $510 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $763 47 payments
  2. Amgen Inc. $717 35 payments
  3. E.R. Squibb & Sons, L.L.C. $639 55 payments
  4. Novartis Pharmaceuticals Corporation $606 29 payments
  5. Janssen Biotech, Inc. $356 38 payments
  6. UCB, Inc. $300 18 payments
  7. DePuy Synthes Sales Inc. $241 11 payments
  8. Genzyme Corporation $202 7 payments
  9. Intrinsic Therapeutics $195 1 payment
  10. Horizon Therapeutics plc $184 14 payments
  11. Other $1,438 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,541 317 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. ORENCIA $639 55 payments
  2. RINVOQ $615 38 payments
  3. COSENTYX $330 21 payments
  4. SIMPONI ARIA $271 33 payments
  5. Cimzia $262 16 payments
  6. EVENITY $250 9 payments
  7. Prolia $238 10 payments
  8. BARRICAID ACD (ANNULAR CLOSURE DEVICE) $195 1 payment
  9. ORTHOVISC $178 8 payments
  10. KEVZARA $169 8 payments
  11. Other $3,263 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

769

Median for Internal Medicine: 777

Drug cost

$819,621

Median for Internal Medicine: $73,373

Branded share of claims

27.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 20 $179,412
Enbrel Sureclick Etanercept Brand 15 $126,419
Enbrel Mini Etanercept Brand 13 $93,577
Humira(Cf) Adalimumab Brand 13 $88,550
Otezla Apremilast Brand 15 $71,276
Orencia Clickject Abatacept Brand 12 $71,151
Actemra Actpen Tocilizumab Brand 15 $68,878
Xeljanz Tofacitinib Citrate Brand 12 $66,881
Teriparatide Generic 11 $26,913
Hydroxychloroquine Sulfate Generic 137 $7,816

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$470,786

Of which drugs: $377,941

Medicare patients

210

Average age 73

Services billed

47,197

145 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 39%
Ischemic heart disease 35%
Depression 25%
Diabetes 19%
Atrial fibrillation 18%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 1,680 $34,592
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 18 1,584 $21,654
Injection, methylprednisolone acetate, 1 mg J1010 Office 35 3,783 $390
Injection, methylprednisolone acetate, 80 mg J1040 Office 13 18 $123

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $162
$162 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $135
$135 — —
TREMFYA
  • Janssen Biotech, Inc. $58
$58 — —
SKYRIZI
  • AbbVie, Inc. $52
$52 — —
KEVZARA
  • GENZYME CORPORATION $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record